BioNTech (BNTX) Q1 2026 earnings summary

Executive summary

• Accelerating late-stage oncology development with over 17 pivotal trial readouts targeted by 2030, focusing on high-incidence cancers such as lung, breast, and solid tumors, and leveraging novel combinations and multiple modalities including ADC, mRNA, and immunotherapy.

• Initiated five additional pivotal trials for pumitamig in collaboration with Bristol Myers Squibb in 2026, and announced a new independent company for next-generation mRNA innovations, with leadership transition planned by end of 2026.

• Oncology pipeline advanced with multiple late-stage assets and partnerships, aiming to become a diversified multi-product oncology company.

• Preparing for the 2026/2027 COVID-19 vaccine season with variant-adapted vaccines and ongoing commercial readiness.

Financial highlights

• Q1 2026 revenues were €118 million, down from €183 million year-over-year, mainly due to lower COVID-19 vaccine demand.

• Operating loss widened to €677 million (IFRS) and €640 million (Adjusted), with net loss at €532 million (IFRS) and €495 million (Adjusted).

• R&D expenses rose to €557 million from €526 million, driven by increased investment in immuno-oncology and ADC programs.

• SG&A expenses increased to €151 million from €121 million, reflecting commercial build-up and integration of acquired operations.

• Ended Q1 with €16.8 billion in cash equivalents and security investments.

Outlook and guidance

• Reaffirmed full-year 2026 revenue guidance of €2.0–2.3 billion, with adjusted R&D expenses of €2.2–2.5 billion and SG&A expenses of €700–800 million.

• Majority of COVID-19 vaccine revenue expected in the last four months of the year; BMS collaboration payment of €613 million to be recognized in Q3.

• Revenue stability expected from collaborations, pandemic preparedness contracts, and service businesses.

• Share repurchase program of up to $1.0 billion planned over the next twelve months.

• Cost savings from manufacturing consolidation expected to reach €500 million annually by 2029.